NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan announced a quarterly dividend on Friday, October 25th. Shareholders of record on Wednesday, November 13th will be paid a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 annualized dividend and a yield of 1.53%. The ex-dividend date of this dividend is Tuesday, November 12th. View Allergan's Dividend History.

Allergan announced that its board has authorized a share repurchase program on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

Allergan plc (NYSE:AGN) announced its earnings results on Tuesday, November, 5th. The company reported $4.25 EPS for the quarter, meeting the Zacks' consensus estimate of $4.25. The company had revenue of $4.03 billion for the quarter, compared to analysts' expectations of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The company's revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business earned $4.25 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share (EPS) guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 brokerages have issued 12 month price objectives for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they anticipate Allergan's stock price to reach $175.90 in the next year. This suggests that the stock has a possible downside of 9.3%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News articles about AGN stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a news impact score of 3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Allergan.

Allergan saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 14,580,000 shares, an increase of 19.2% from the December 15th total of 12,230,000 shares. Based on an average trading volume of 2,220,000 shares, the short-interest ratio is presently 6.6 days. Approximately 4.5% of the company's stock are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Calamos Advisors LLC (0.11%), Metropolis Capital Ltd (0.06%), Advisors Capital Management LLC (0.04%), Tocqueville Asset Management L.P. (0.03%), Arvest Bank Trust Division (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including United Services Automobile Association, Neville Rodie & Shaw Inc., State of Alaska Department of Revenue, Tocqueville Asset Management L.P., Alpine Global Management LLC, Diversified Trust Co, Woodstock Corp and Arvest Bank Trust Division. View Insider Buying and Selling for Allergan.

AGN stock was acquired by a variety of institutional investors in the last quarter, including Syquant Capital Sas, Calamos Advisors LLC, Metropolis Capital Ltd, Moon Capital Management LLC, Modus Advisors LLC, Legacy Private Trust Co., Tuttle Tactical Management and BKD Wealth Advisors LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $193.83.

Allergan has a market capitalization of $63.63 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]